Operational Cures After Interferon-Alpha in Patients with Chronic Myeloid Leukemia in Central and Northern Moravia
| Autor: | Edgar, Faber, Adam, Kuba, Jana, Zapletalová, Martina, Divoká, Šárka, Rožmanová, Peter, Rohoň, Milena, Holzerová, Marie, Jarošová, Karel, Indrák, Jarmila, Živná |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Short Communication Immunology Treatment outcome Fusion Proteins bcr-abl Alpha interferon Antiviral Agents Gastroenterology Disease-Free Survival Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Virology Internal medicine Biomarkers Tumor medicine Humans In patient Complete Cytogenetic Response Pathology Molecular Myeloid Progenitor Cells Survival analysis Czech Republic business.industry Follow up studies Interferon-alpha Myeloid leukemia Negativity effect Cell Biology Middle Aged Survival Analysis Surgery Treatment Outcome Female business Follow-Up Studies |
| Zdroj: | Journal of Interferon & Cytokine Research. 32:230-234 |
| ISSN: | 1557-7465 1079-9907 |
| DOI: | 10.1089/jir.2011.0108 |
| Popis: | We assessed long-term outcome of 118 consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (IFN-α) in the Central and Northern Moravia region between 1989 and 2006 with focus on operational cure. The median follow-up was 82.6 months (range 12.4–212.6). Eighteen (15.3%) patients achieved complete cytogenetic response (CCyR) after median 16.7 (3.7–40.8) months. Nine of these patients (7.6%) achieved BCR-ABL negativity in nested reverse transcriptase–polymerase chain reaction [“complete” molecular response (CMR)] and 6 of them have been operationally cured without any treatment for median 6 (4–10) years, while 2 continue with IFN-α and 1 died from CML-unrelated cause. Operationally cured patients had a significantly lower percentage of initial peripheral promyelocytes, blasts, and erythroblasts than the rest of patients treated for more than 12 months (P=0.01–0.03). Unlike patients with sole CCyR, the majority of whom lost CCyR despite continuing IFN-α therapy and required imatinib, patients who achieved CMR had excellent long-term outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|